Turion Labs launches in Singapore to accelerate biotech across Southeast Asia

Turion Labs, a joint venture backed by Korea’s S&S LAB and Indonesia’s Future Lestari, officially launched in Singapore this week during Ecosperity Week, unveiling plans to build Southeast Asia’s first full-stack biotech innovation platform.

The venture brings together modular laboratories, contract research services, and regulatory support into a single, integrated ecosystem designed to support medical and life sciences companies from discovery through to commercialization.

“We’re bridging the gap between high-potential science and scalable solutions,” commented Dominic Jeong, CEO of S&S LAB Korea. “With Southeast Asia as our launchpad, we are building a connected platform that empowers global biotech innovators to gain access to Korean R&D excellence, Southeast Asian market pathways, and world-class lab infrastructure.”

Turion Labs' flagship facility is set to open later this year at the Sinarmas Land Biomedical Hub in BSD City, Indonesia – a location recently designated as a Biomedical Special Economic Zone. The site will house modular lab spaces, pilot-scale R&D units, and clinical support services aimed at supporting emerging biotech and biomedical technology startups.

“Turion Labs is a platform for acceleration – a place where biotech ideas become real-world impact,” added Cynthia Krisanti, Director of Future Lestari. “We are creating a robust ecosystem for regional and global innovators, enabling faster product development, streamlined regulation, and expanded market access, all rooted in Southeast Asia.”

The initiative aims to address key bottlenecks in the biotech development pipeline, such as limited access to regulatory infrastructure, fragmented research capabilities, and insufficient support for scaling. By embedding all core services into a shared platform, Turion Labs intends to lower barriers for startups and mid-stage companies while attracting cross-border investment and partnerships.

Turion Labs’ model is particularly focused on making Southeast Asia more competitive as a biotech hub. While the region has strong academic and scientific talent, companies often face hurdles in translating innovation into viable commercial products. The combination of Korean R&D and Indonesian infrastructure is intended to help close that gap, while Singapore’s strategic location adds further global connectivity.

The launch event was attended by His Excellency Professor Dr Pratikno, Indonesia’s Coordinating Minister for Human Development and Cultural Affairs, who voiced his support for the platform. He emphasized its potential to accelerate innovation in health and nutrition, key areas for regional development and resilience.

Looking ahead, Turion Labs plans to expand beyond its initial bases in Singapore and Indonesia. Projects are already being scoped in Thailand, Malaysia, and the Philippines, forming the foundation of a distributed biotech corridor. The aim is to connect regional research hubs, reduce time-to-market for biotech products, and attract long-term venture capital and strategic investment.

Turion Labs is positioning itself not just as an infrastructure provider, but as a regional catalyst – one that supports startups and scaleups with the tools they need to succeed in an increasingly global and competitive biotech landscape.